1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Bristol Claims A First With Opdivo In Neoadjuvant NSCLC

Co-Primary Endpoint Data May Support Early Approval

 
• By Mandy Jackson

More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.

closeup of a young caucasian doctor man sitting at his office desk observing a chest radiograph in a tablet computer
Opdivo plus chemo had higher response rates in neoadjuvant lung cancer than chemo alone • Source: Shutterstock

Bristol Myers Squibb Company claimed an immunotherapy first on 7 October when it reported top-line results from the Phase III CheckMate-816 clinical trial, as the first company to show that a checkpoint inhibitor-based combination therapy in the neoadjuvant setting was superior to chemotherapy in a Phase III study of resectable non-small cell lung cancer.

The company reported that more NSCLC patients who received Opdivo (nivolumab) plus chemotherapy as a neoadjuvant treatment had a pathologic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer